Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2015

01-12-2015 | Thoracic Oncology

Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?

Authors: Masayuki Watanabe, MD, PhD, FACS, Shinji Mine, MD, Koujiro Nishida, MD, PhD, Kazuhiko Yamada, MD, PhD, Hironobu Shigaki, MD, PhD, Akira Matsumoto, MD, Takeshi Sano, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2015

Login to get access

Abstract

Purpose

The aim of this study was to identify good candidates for salvage esophagectomy after definitive chemoradiotherapy (dCRT), based on safety and survival.

Methods

Sixty-three patients who underwent salvage esophagectomy, after dCRT, at the Cancer Institute Hospital, Tokyo, Japan, between 1988 and 2013, were retrospectively analyzed. Short-term outcomes were evaluated by reviewing postoperative complications, length of postoperative hospital stay, and mortality. Survival rates were calculated using the Kaplan–Meier method, and statistical significance was determined using the log-rank test. The Cox proportional hazards model was used for univariate and multivariate analyses of overall survival. Univariate logistic regression analysis was used to identify factors related to R0 resection.

Results

Postoperative complications occurred in 41 patients (65.1 %), and the mortality rate was 7.9 %. In-hospital deaths did not occur among patients with less advanced tumors prior to dCRT (cT1–2 and cN0), or among those who had previously achieved a complete response (CR); the 3- and 5-year overall survival rates were 29.8 % and 15.0 %, respectively. Univariate analysis revealed that residual disease, tumor depth, dCRT response, lymph node metastasis, and time to relapse were significant factors affecting overall survival. Multivariate analysis demonstrated that R0 resection and ypT0–2 tumors were significant, favorable prognostic factors in patients undergoing salvage esophagectomy. In addition, cT1–2 tumors, initially resectable tumors, ycT1–2 tumors, and relapse after CR were factors predicting R0 resection.

Conclusions

Based on both short- and long-term outcomes, patients with pretreatment or preoperative T1–2 tumors and those with relapse after CR are good candidates for salvage esophagectomy.
Appendix
Available only for authorised users
Literature
1.
Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.CrossRefPubMed
2.
Kato K, Muro K, Manashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.CrossRefPubMed
3.
Ohtsu A, Baku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.PubMed
4.
Yamamoto S, Ishihara R, Motoori M, et al. Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. Am J Gastroenterol. 2011;106:1048–54.CrossRefPubMed
5.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–7.CrossRefPubMed
6.
Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.CrossRefPubMed
7.
Smithers BM, Cullinan M, Thomas JM, et al. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy. Dis Esophagus. 2007;20:471–7.CrossRefPubMed
8.
Meunier B, Raoul J, LePrise E, et al. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg. 1998;15:224–6.CrossRefPubMed
9.
Tomimaru Y, Yano M, Takachi K, et al. Factors affecting prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol. 2006;93:422–8.CrossRefPubMed
10.
Oki E, Morita M, Kakeji Y, et al. Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer. Dis Esophagus. 2007;20:301–4.CrossRefPubMed
11.
Nishimura M, Daiko H, Yoshida J, Nagai K. Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg. 2007;55:461–5.CrossRefPubMed
12.
Nakamura T, Hayahsi K, Ota M, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188:261–6.CrossRefPubMed
13.
Chao YK, Chan SC, Chang HK, et al. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol. 2009;35:289–94.CrossRefPubMed
14.
Miyata H, Yamasaki M, Takiguchi S, et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol. 2009;100:442–6.CrossRefPubMed
15.
Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–84.CrossRefPubMed
16.
Wilson KS, Wilson AG, Dewar GJ. Curative treatment for esophageal cancer: Vancouver Island Cancer Center experience from 1993 to 1998. Can J Gastroenterol. 2002;16:361–8.PubMed
17.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2010.
18.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of survey. Ann Surg. 2004;240:205–13.PubMedCentralCrossRefPubMed
19.
Tachimori Y. Salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg. 2009;57:71–8.CrossRefPubMed
20.
Hofstetter WL. Salvage esophagectomy. J Thorac Dis. 2014;6:S341–9.PubMed
21.
Morita M, Kumashiro R, Hisamatsu Y, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol. 2011;46:1284–91.CrossRefPubMed
22.
Wang S, Tachimori Y, Hokamura N, et al. Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: the importance of lymphadenectomy. J Thorac Cardiovasc Surg. 2014;147:1805–11.CrossRefPubMed
23.
Honing J, Smit JK, Muijis CT, et al. A comparison of carboplatin and paclitaxel with cisplatin and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25:638–43.PubMedCentralCrossRefPubMed
24.
van Hagen P, Hulschof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
25.
Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014;89:872–9.CrossRefPubMed
Metadata
Title
Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?
Authors
Masayuki Watanabe, MD, PhD, FACS
Shinji Mine, MD
Koujiro Nishida, MD, PhD
Kazuhiko Yamada, MD, PhD
Hironobu Shigaki, MD, PhD
Akira Matsumoto, MD
Takeshi Sano, MD, PhD
Publication date
01-12-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 13/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4556-6

Other articles of this Issue 13/2015

Annals of Surgical Oncology 13/2015 Go to the issue

Colorectal Cancer

Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray

Gynecologic Oncology

Improving Sentinel Lymph Node Detection in Patients with Cervical Cancer

Head and Neck Oncology

Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?

Gynecologic Oncology

Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift

Hepatobiliary Tumors

Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy

Gastrointestinal Oncology

Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases